Challenges in Treating Metastatic Urothelial Cancer: A Geriatric Perspective

News
Video

Expert insight into the complexities of managing metastatic urothelial cancer in geriatric patients with comorbidities, highlighting the importance of aggressive therapy in improving survival outcomes.

Case: A 73-Year-Old Man with Metastatic Urothelial Carcinoma

Initial Clinical Presentation:

  • A 73-year-old man presented to you from their local urologist with dizziness and hematuria
  • PMH: hypertension and diabetes (uncontrolled)
  • SH: former smoker; consumes alcohol 2-3 times per week
  • Chest x-ray and CT revealed a 3.7-cm mass on the right lateral wall of the bladder and liver metastases
  • Cystoscopic biopsy/pathology confirmed stage IV urothelial carcinoma
  • ECOG PS 1
  • CrCl 65 mL/min
  • The patient received gemcitabine + cisplatin (6 cycles)
    • Partial response at completion of chemotherapy
    • No maintenance therapy given, although discussed with patient

Current Clinical Presentation:

  • 7 months later, disease progression was discovered on routine follow up imaging

Treatment:

  • The patient received pembrolizumab and a partial response was achieved at 6 cycles
  • Molecular testing showed no FGFR2 mutation or fusion
Related Videos
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Andrew Kuykendall, MD, an expert on polycythemia vera
Prithviraj Bose, MD, an expert on myelofibrosis
Prithviraj Bose, MD, an expert on myelofibrosis
Related Content
New Study Shows Disparity in Prostate Cancer Treatment and Survival

New Study Shows Disparity in Prostate Cancer Treatment and Survival

April 16th 2024
Article

A new study found that Black patients with prostate cancer were less likely to get new treatments and had a higher risk of death than White patients.

Read More

Dizman’s Global Pursuit to Cancer Research and Understanding

Dizman’s Global Pursuit to Cancer Research and Understanding

April 1st 2024
Podcast

In this episode of Emerging Experts, Nazli Dizman, MD, shares the intricacies of her journey towards becoming an oncologist in the United States.

Listen

NCCN Recommends First AI Prognostic Tool in Prostate Cancer

NCCN Recommends First AI Prognostic Tool in Prostate Cancer

March 5th 2024
Article

The National Comprehensive Cancer Network has included ArteraAI in its clinical practice guidelines as a predictive test for localized prostate cancer.

Read More

A Deep Dive Into the Evolving Landscape of Prostate Cancer

A Deep Dive Into the Evolving Landscape of Prostate Cancer

January 15th 2024
Podcast

In season 5, episode 1 of Targeted Talks, Badrinath Konety, MD, delves into the critical topic of prostate cancer screening and discusses some of the recent advancements in the prostate cancer space.

Listen

Subcutaneous Nivolumab Delivers Clinical Equipoise to Standard IV Dosing in ccRCC

Subcutaneous Nivolumab Delivers Clinical Equipoise to Standard IV Dosing in ccRCC

January 27th 2024
Article

Subcutaneous nivolumab coformulated with rHuPH20 showed noninferiority of PK exposures compared with intravenous nivolumab in metastatic ccRCC.

Read More

Adjuvant Pembrolizumab Notably Improves OS vs Placebo in ccRCC

Adjuvant Pembrolizumab Notably Improves OS vs Placebo in ccRCC

January 27th 2024
Article

Adjuvant pembrolizumab treatment significantly improved overall survival vs placebo in patients with clear cell renal cell carcinoma.

Read More